Policy & Regulation
Kineta successfully completes FDA pre-IND meeting for KVA12.1
28 July 2021 -

Kineta Inc, a clinical stage biotechnology company, announced on Tuesday that it has successfully completed a pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration (FDA) for the manufacturing, preclinical and clinical development plan for KVA12.1.

According to the company, it has gained alignment with FDA on the initial Phase 1/2 clinical trial of the safety and efficacy of its KVA12.1 as a single agent and in combination with pembrolizumab in patients with unresectable or metastatic solid tumours.

The firm plans to start the Phase 1/2 first-in-human clinical studies in mid-2022.

Login
Username:

Password: